2018, Number 3
Rev Hematol Mex 2018; 19 (3)
Ron-Guerrero CS, Ron-Magaña AL, López-Flores JF
PDF size: 295.18 Kb.
ABSTRACTBackground: Anemia of chronic disease is the first cause of anemia in hospitalized patients. It is usually associated with a chronic inflammatory disease.
Objective: To test the effectiveness of thalidomide in increasing hemoglobin levels in patients with anemia of chronic disease.
Material and Method: A clinical study was done with adult women with anemia of chronic disease from the Hematology clinic of the General Hospital Dr. Aquiles Calles Ramírez, Nayarit, Mexico, from February 1st 2015 to January 31 2017. They were assigned by convenience in three groups, to administer ferrous sulfate (FS), thalidomide or ferrous sulfate and thalidomide, respectively. They were followed for 90 days after having collecting their baseline laboratory measurements. Hemoglobin means and hematological data were compared using the parametric tests of ANOVA and Student t test, or in case of not fulfilling the assumption of normality, the Kruskal-Wallis and Mann-Whitney U tests were used.
Results: The average hemoglobin level in patients treated with thalidomide increased from 10.5 ± 0.66 to 11.9 ± 1.05 g/dL, with ferrous sulfate increased from 10.1 ± 1.25 to 11.5 ± 0.87 g/dL and with thalidomide/ferrous sulfate increased from 9.5 ± 0.96 to 11.8 ± 1.28 g/dL. The significance was p ‹ 0.001 in each of the arms.
Conclusion: Thalidomide is effective in anemia of chronic disease and shows synergism when ferrous sulfate is added.